Abstract |
In 20 patients with inducible ventricular tachycardia (VT), intravenous bretylium tosylate infused as a 10-mg/kg bolus followed by 2 mg/min caused no change in refractory periods and did not suppress inducibility of VT. The use of bretylium for the treatment of VT should be reexamined.
|
Authors | S Chandrasekaran, J S Steinberg |
Journal | The American journal of cardiology
(Am J Cardiol)
Vol. 83
Issue 1
Pg. 115-7, A9
(Jan 01 1999)
ISSN: 0002-9149 [Print] United States |
PMID | 10073797
(Publication Type: Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Anti-Arrhythmia Agents
- Bretylium Tosylate
|
Topics |
- Anti-Arrhythmia Agents
(adverse effects, therapeutic use)
- Bretylium Tosylate
(adverse effects, therapeutic use)
- Female
- Hemodynamics
(drug effects)
- Humans
- Hypotension
(chemically induced)
- Male
- Middle Aged
- Prospective Studies
- Severity of Illness Index
- Syncope
(etiology, physiopathology, prevention & control)
- Tachycardia, Ventricular
(complications, drug therapy, physiopathology)
- Treatment Failure
|